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Abstract
Aim This paper summarizes the deficiencies and weak-
nesses of the most frequently used methods for the
allocation of health-care resources. New, more transparent
and practical methods for optimizing the allocation of these
resources are proposed.
Method The examples of quality-adjusted life years
(QALYs) and efficiency frontier (EF) are analyzed to
describe weaknesses and problems in decisions regulating
health-care provision. After conducting a literature search
and discussions with an international group of professio-
nals, three groups of professionals were formed to discuss
the assessment and appraisal of health-care services and
allocation of available resources.
Results At least seven essential variables were identified that
should be heeded when applying the concept of QALYs for
decisions concerning health-care provision. The efficiency
frontier (EF) concept can be used to set a ceiling price and
perform a cost-benefit analysis of provision, but different
stakeholders—a biostatistician (efficacy), an economist
(costs), a clinician (effectiveness), and the patient (value)—
could provide a fairer appraisal of health-care services.
Efficacy and costs are often based on falsifiable data.
Effectiveness and value depend on the success with which a
particular clinical problem has been solved. These data cannot
be falsified. The societal perspective is generated by an
informal cost-benefit analysis including appraisals by the
above-mentioned stakeholders and carried out by an autho-
rized institution.
Conclusion Our analysis suggests that study results
expressed in QALYs or as EF cannot be compared unless
the variables included in the calculation are specified. It
would be far more objective and comprehensive if an
authorized institution made an informal decision based on
formal assessments of the effectiveness of health-care
services evaluated by health-care providers, of the value
assessed by consumers, of efficacy described by biostatis-
ticians, and of costs calculated by economists.
Keywords Health-care appraisal . Patient’s value .
Society’s benefit
Introduction
The original objectives of health-care systems were to
prevent illnesses and health-related problems and help those
already affected to recover. We seem, however, to have lost
track of these original objectives. Gawande (2009)
describes the change of the health-care system into a purely
commercial business in some parts of the USA. The
commercialization of medicine challenging health-care
systems everywhere runs counter to traditional medical
professionalism (Irvine 2001). Consequently, the European
Commission has defined accessibility, quality, and sustain-
ability as long-term objectives for national health-care
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systems (http://ec.europa.eu/health-eu/care_for_me/long_
term_care/index_en.htm).
These objectives can be achieved if we (patients,
physicians, nurses, social workers, insurance companies,
and the pharmaceutical industry) reject unreasonable
demands and refrain from creating unbeneficial new ones.
Some health-care providers claim to optimize health-care
delivery (Porzsolt and Kaplan 2006), but actually only
drain health-care resources. As a result, these conflicting
interests are making the structure of the health-care system
increasingly complex.
Politicians are expected to provide a framework guaran-
teeing equal access and sufficient financial support while
avoiding moral hazard and abuse of the system. An
overview (Zentner 2005) investigating the framework of
decision-making in 11 national health-care systems found it
difficult to describe the actual procedures involved and the
roles of the different participants, although several countries
have developed codified processes to make health-care
decisions. Some systems collect data on medical outcomes
to support the statistical comparison of medical interven-
tions. The British National Health Service (NHS) provides
a quality-and-outcomes framework based on the annual
assessment of patients with chronic diseases (http://www.
gpcontract.co.uk). In Germany, the first analyses of the
Disease Management Programs (DMP) are available and
indicate room for improvement (Joos 2005; Szecsenyi
2008; Porzsolt 2008a).
Transparency is essential in complex, regulated systems
like public health-care systems; it has the same function in a
regulated system as competition does in a market-based
system (Porzsolt 2009a). Because a lack of transparency in
regulated systems increases the risk of ineffectiveness, the
Healthcare Forum of the Federal State of Baden-
Wuerttemberg in Germany established a project group to
perform two tasks: to identify the weaknesses of the
available methods (Zentner 2005) for allocation of health-
care resources and propose strategies to optimize these
methods.
This paper describes the deficiencies of the methods
most frequently used to allocate health-care resources, and
tools and methods to be developed to optimize this
allocation.
Methods
Following a literature search (keywords: public choice, health
economics, decision making, evidence-based medicine,
health-care policy, expert panels, guidelines, clinical path-
ways, patient-related outcomes, shared decision-making,
health-technology assessment) and discussions with an
international group of health-care professionals, we organized
the three following discussion groups: the Clinical Economics
Group at the University of Ulm consisting of academic
teachers and medical students; practitioners, scientists, and
managers invited by the Healthcare Forum of the Federal State
of Baden-Wuerttemberg to discuss new concepts for assess-
ment and appraisal of individual and societal health-care
benefits; and an international group of scientists who had
previously cooperated either in joint projects on evidence-
based medicine or on health-related quality of life.
The discussion in all three groups began with the
identification of deficiencies in the most frequently used
methods—the calculation of quality-adjusted life years
(QALYs) and of the efficiency frontier (EF)1, which is
recommended by the Institute for Quality and Efficiency in
Healthcare (IQWiG) in Germany. We included the results of
a Health Technology Assessment (HTA) report by Zentner
et al. (2005) analyzing the methods used to assess the value
of health-care services in 11 countries. We then tried to
combine the rather controversial ideas and proposals by
searching for compromises.
Results
During the preliminary discussions, the deficiencies and
weaknesses of the two above-mentioned methods for
allocation of health-care resources (QALYs and EF) were
summarized. A new strategy based on four different
assessments was then proposed. This procedure is both
more transparent and practical for reaching everyday
decisions than the other methods.
Variables influencing the formal descriptions of health-care
value
One of the most frequently used methods to describe
beneficial health-care treatment is the calculation of QALYs
(Drummond 1997). It is applicable in almost any clinical
situation and provides cardinal values (time-adjusted
utilities) that can be linked to monetary units, as well as
the relationship between time-adjusted utilities and costs,
which can be used to allocate resources. The concept and
problems of QALYs have been extensively discussed
(Robine 1993; Erickson 1994; Benson 1998; Prieto 2003).
The method frequently lacks transparency when applied in
daily practice. The approaches used for collection of data
on utilization include subject interviews, subject surveys,
1 This describes the monetary cost in relation to any selected effect, e.g.,
the absence of gastrointestinal reflux or percent reduction in low-density
lipoprotein concentration. It is used in the finance sector as a capital-asset
pricing model (Markowitz 1999) and occasionally adapted to health
care.
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provider surveys, reviews of medical records, health-care
utilization diaries, and insurance claims (Goossens 2000).
This wide spectrum of methods results in a common
denominator, the QALY, which is used as a basis for
making decisions concerning the allocation of health-care
resources. It is, however, almost impossible to confirm the
comparability of data from two different calculations
without describing the variables influencing them. In most
studies in which QALYs are calculated, quality of life is
self assessed, although proxy ratings are also used. Several
studies have revealed considerable differences between self
assessments and proxy ratings (Geldmacher 2008). Due to
these inconsistent findings, some authors recommend exclud-
ing proxy ratings when calculating QALYs (Muennig 2006).
A survey by Furlong (2005) describes substantial differences
among various measurements.
QALYs are not generally accepted by decision makers in
all countries for a number of reasons. The German Institute
for Quality and Efficiency in Healthcare (IQWiG) prefers to
calculate the EF instead of QALYs for the allocation of
health-care resources (http://www.iqwig.de/index.2en.html)
for three reasons: to provide information to the political
authority for setting the ceiling price at which a superior
health technology in a given therapeutic area should
continue to be reimbursed, to address the benefits of
treatment relative to costs for a given indication, and to
consider health benefits in the economic assessment as
published in IQWiG’s methods (Caro 2008).
The literature search and our discussion groups identi-
fied at least seven variables that influence the description of
(patient-related) outcomes, i.e., in quantity and quality of
life and outputs, i.e., surrogates of outcomes. As a
consequence, any scientific report that describes the
efficacy and effectiveness of health-care services can
specify these seven variables. These variables refer to the
self or proxy rating, the perspective, the characteristics of
the instrument for QoL assessment, the setting in which the
assessment takes place, confirmation of the validity of the
assessment, application of Bayes’ principles (calculating
the change relative to the individual baseline instead of
using cardinal values), and whether or not the preferences
of individual patients are taken into consideration.
Necessary specifications of variables
The necessary specifications of these variables are listed in
Table 1. The effects of health-care services can be self
assessed or proxy rated. If proxy ratings are used, it should be
specified whether the perspective is limited to a single
laboratory result or a single functional test. A multidimen-
sional perspective may be provided by assessment of quality
of life, medical results, side effects of treatment, and treatment
costs. The assessment may be performed by a single
researcher or by a multidisciplinary team, including econo-
mists, psychologists, clinicians, and patients. Such assess-
ments would represent a much broader view by including both
providers and consumers. Several studies have shown that
assessments made under the ideal conditions of a controlled
clinical trial generate different results than the same trial
completed under everyday conditions (Summerfelt 1998;
Davidson 2006; Amin 2004; Wolraich 1999). Therefore, it
is essential to describe whether the data were generated
Table 1 Variables that contribute to either under- or overestimation of outputs and outcomes, e.g., in the process of computing QALYs. Under- or
overestimation cannot be predicted, as it depends on the rater’s expectation and on the topic condition being rating
Causes of under- or overestimation of rating results
Perspective Proxy rating Self-assessment
Proxy perspective Mono- or oligodimensionala Multidimensionala
QOL instrument Specificb Genericb
Setting Ideal conditions, such as in a clinical trial Everyday conditions
Validity confirmed Noc Yesc
Bayes’ principle Considering patients’ baseline conditionsd Considering cardinal valuesd
Evaluation of results Respecting individual patients’ perceptions Not respecting individual patients’ perceptions
a A mono- or oligodimensional perspective (e.g., limited to a single laboratory result or an improvement in a single physical function) often
prevails in individual disciplines. A multi-dimensional perspective (e.g., quality-of-life-related results, plus medical results, plus therapeutic
burden, plus monetary costs) is more common in a multidisciplinary team including economists, psychologists, doctors, and patients, thereby
representing the views of both providers and consumers
b Generic quality-of-life (QoL) instruments are ideal to compare different services, but lack the sensitivity and specificity to detect many
differences in treatment results
c Validity refers both to the rigor with which a study has been conducted and to the general transferability and applicability of its results
d The same absolute advantage may imply a life-saving difference for a severely ill patient or may be almost meaningless for a nearly healthy
individual. Similar objective advantages may receive highly different subjective evaluations from patients with different individual preferences.
Increased investments in a given therapy may gain diminishing marginal utility
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under conditions similar to those under which the data will
be applied. As up to 80 percent of scientific reports lack
validity, i.e., overestimate the size of the described effects
(Barreto 2005; Atashili 2006; Hallfors 2006; Steg 2007),
there is a growing need to apply standardized methods to
confirm the validity of reported results (Bombardier 1999;
Glasgow 2003; Akobeng 2008). Different groups of patients
have different needs and preferences. Therefore, the evalu-
ation of health services, i.e., which of the patient’s problems
can be solved by a particular service, seems highly important
for decision making.
How to avoid formal calculations of the public benefit
of health care
As authentic decisions about the value of health-care
services depend on the perspectives of the decision makers,
the perspectives of several different stakeholders should be
taken into consideration. Table 2 contains the perspectives
of four stakeholders—scientists (e.g., biostatisticians),
payers (e.g., economists of health insurances), health-care
providers (e.g., doctors), and health-care consumers (e.g.,
patients). These four stakeholders make different decisions
when assessing the value of health-care services. Therefore,
it is necessary to combine their decisions into a single
public decision, which can only be done by a legally
authorized institution. The details of the organization will
differ in different countries (Zentner 2005).
The proposed solution is based on the assumption that
the final public decision about health-care provision is too
complex to be formalized. Figure 1 demonstrates that
complex problems, such as calculation of the bearing
capacity of a bridge, require expert knowledge. More
complex problems, like predicting the future course of
shares, may be solved as accurately by expert knowledge as
by gut feelings (Gigerenzer 2007). Although the final
political decisions in health-care provision are rather
complex and cannot be made formally, the decisions of
various stakeholders that provide the basis for the political
decisions may at least partially be reached in a formal way.
Table 2 shows that different stakeholders provide different
expertise, use different comparators and endpoints for their
assessments, consider different settings, and apply different
criteria to make their decisions.
Statements by biostatisticians and economists are avail-
able for almost any health service, whereas systematic
statements by health-service providers and consumers are
rare in the scientific literature. The value of health care
from the doctor’s and the patient’s points of view could be
documented if doctors and patients explicitly define the
problem to be solved by the care provided and the average
time interval within which the problem is expected to be
solved. Doctors and patients should initially provide state-
ments on the degree to which the defined problem could be
solved (completely, partially, barely, not at all, or with new
additional problems emerging). We have already started the
first projects in which doctors and patients define the main
problem, treatment goal, and the parameters that reliably
indicate the degree of goal attainment (Porzsolt 2009b). The
descriptions of the degrees of goal attainment from the
doctors’ and the patients’ points of view can be used as two
separate indicators for the overall quality of a treatment.
The difficulty of making adequate and equitable decisions
about health-care provision becomes evident, as statements
that can be falsified a priori are not better than those that
cannot be falsified. The final decision about publicly
Table 2 The four dimensions of health-care assessments and appraisals provide the basis for the fifth dimension of societal benefit. This fifth
dimension is the result of a democratic decision based on the results of the four previous assessments
Efficacy Costs Effectiveness Value Benefit
Perspective Biostatistician Economist Provider Recipient Societya
Expertise Preclinical experts Clinical experts Decision makers
Compared
alternative
Best available
treatment
Opportunity
costs
Provider’s
experience
Recipient’s
experience
Opportunity costs and
valueb
Endpoints Outputs or outcomesc Monetary costs Health-care providers may report outputs or
outcomesc (effectiveness), but recipients
should address outcomesc (value)
Societal objectives
Setting Ideal but artificial study conditions Real-world, everyday conditions
Criteria for
evaluation
Statements that can be falsified Statements that cannot be falsified
a Society has to decide about the mix of market competition and government regulation
b The perceived value is not independent from the provided information. Both the costs and the provided information will vary among different
societies
c Outputs are defined here by surrogate parameters, such as blood pressure or laboratory results (without confirmed effects on quantity or quality
of life), while outcomes represent patient-related outcomes, such as the confirmed reduction of strokes due to reduced blood pressure in a defined
risk group
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financed health care is based on a cost-benefit analysis, i.e.,
the societal value of health services as related to monetary
units. This societal decision can only be made by an
authorized institution.
Discussion
Cost-effectiveness research is the comparative analysis of
two or more alternative interventions in terms of their
health and economic consequences. The results are
expressed as an incremental cost-effectiveness ratio, i.e.,
the ratio of differences in costs between a pair of medical
interventions to the differences in the corresponding health
effects. This definition is well accepted, but includes neither
the patients’ goals nor their assessment by the patients
(Biswas 2008a, b). The vast majority of everyday decisions
in health care are made by health-care providers (e.g.,
doctors). As various health-care professionals claim the
right to make health-care decisions, it seems important to
define the necessary qualifications for making these
decisions. Some of the emerging problems are not directly
related to health care, but to the wider context of health-
care provision.
One problem is nomenclature because different disci-
plines use different concepts or terms for essentially the
same thing or the same term for something entirely
different. An example is the different meanings of ‘effi-
ciency’ in pharmacology (Chu 2004), physics, technology,
and epidemiology (Last 1988). Within a particular disci-
pline, differences that are not generally recognized may,
however, be important. An example is the difference
between cardinal and ordinal utility. It is well known that
only cardinal utilities can be used for multiplications that
are made in the calculation of QALYs. Awareness of this
problem is essential for all stakeholders to avoid mistakes.
A second problem in decisions about the allocation of
health-care resources is the translation of decisions into
everyday practice. Practitioners, ethicists, and other health-
care professionals have to be aware of the limited validity
of a considerable portion of the scientific literature (Bailey
2004; Hailey 2004; Howley 2008). Critical comments made
by various stakeholders, the systematic documentation of
treatment goals, the time within which the desired response
is expected, and the observed treatment outcome (from both
the physician’s and the patient’s perspective) should be
introduced into day-to-day practice. This is easier said than
done, as our usual strategies address the structure and the
process, but not the intended outcomes achieved by health-
care services.
The cursory understanding of the QALY concept creates
a considerable risk of drawing wrong conclusions and
consequences in health-care decisions. Experts (i.e., those
who calculate and publish data on QALYs) are usually
aware of these problems, but do not always take the
necessary and adequate limitations into account when
interpreting QALY results. A second problem is that the
majority of users (i.e., those who don’t calculate but use
results expressed in QALYs) have only vague knowledge
about the limitations of this concept. Therefore, more
transparency is needed when reporting results on health-
care assessments.
This publication suggests a new approach that may apply
to different health-care systems, as it addresses the conflict
between the individual patient’s value judgment, which is
advocated by some lobbyists, and societal benefit, which is
publicly advocated. The method we propose to settle this
difference is based on four steps. First, the weakness and
lack of transparency of one of the most frequently used
methods for allocation of health-care resources has to be
described. Second, four stakeholders are requested to
provide a formal evaluation of the health-care service in
question from their own perspectives using their preferred
endpoints, conditions, and dimensions. Third, the formal
evaluations of the four stakeholders are presented to an
authorized institution. Fourth, this institution has to convert
the evaluations from the four specialist fields into a societal
consensus.
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Expertise 
General 
Knowledge
Simple [Question] Complex
Small [Number of variables] Large
Objective [Assessment] Subjective
Fig. 1 General hypothetical relationship between required knowledge
and complexity of the problem. Rational explanations may be
sufficient to solve problems up to a certain complexity. Very complex
problems may be solved as efficiently by gut feelings as by evidence-
based decisions
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